Bristol-Myers Squibb (NYSE:BMY) has received mixed analyst ratings in the last quarter with 3 bullish, 2 somewhat bullish, 8 indifferent, and 2 somewhat bearish ratings. The average price target is $63.13, representing an upside from the current price of $50.555. This target has decreased by 4.51% from the previous target of $66.11. Analysts rate stocks based on research and provide guidance to investors, though their predictions are opinions and subject to human error.